<DOC>
	<DOCNO>NCT00763763</DOCNO>
	<brief_summary>Patients previously expose imatinib resistant refractory Ph+ ALL , lymphoid blast crisis chronic myelogenous leukaemia ( LBC CML ) de novo Ph+ ALL age 55y eligible study . The DIV regimen consist one IV injection vincristine 2 mg combine 2 day dexamethasone 40 mg PO repeat weekly 4 week induction monthly 4 month consolidation . Imatinib administer 800 mg per day induction period 600 mg/d continuously consolidation . Patients CR eligible HSCT allocate maintenance therapy consist weekly SC injection Pegasys 45 µg continuous administration imatinib 400 mg per day 2 year .</brief_summary>
	<brief_title>Imatinib Mesylate With Vincristine Dexamethasone Acute Lymphoblastic Leukemias With BCR-ABL Positive</brief_title>
	<detailed_description>Gleevec™ consider gold standard treatment chronic phase chronic myeloid leukemia ( CML ) , patient candidate allogenic bone marrow transplantation . However , advanced phase CML Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph+ ALL ) , development resistance imatinib become central issue concern use imatinib monotherapeutic agent . The response rate ( complete hematological remission ) dose 600 mg/d poor prognosis lymphoid blast phase CML Ph+ ALL 20 % median time disease progression 2.2 month . In VITRO study address question combine therapy imatinib . A synergistic additive activity demonstrate vincristine dexamethasone , two major drug treatment acute lymphoblastic leukemia ( ALL ) . On go clinical study also test Gleevec™ association daunorubicin cytarabine ( standard dose ) CML myeloid blast phase ( CST571AFR01 ) MITHOXANTROME cytarabine ( intermediate dose ) consolidation regiment Ph+ ALL first CR ( CSTI571AFR03 ) . The safety combine therapy excellent two study . Therefore , propose initiate study assess efficacy safety Gleevec™ combine vincristine dexamethasone patient relapse refractory Philadelphia chromosome-positive acute lymphoblastic leukemia</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female subject 18 year , Poor prognosis BCRABL transcriptpositive acute lymphoblastic leukemia ( refractory relapse Ph+ ALL , BP lymphoid CML , BP lymphoid CML relapse ) Pregnant female , Blastic involvement CNS , Participation investigational agent trial within 4 week , High dose therapy within 4 week , Gleevec administration within 3 month , Transaminases grade 3 4 elevation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Leukemia , Lymphocytic , Acute</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>Blast Crisis</keyword>
	<keyword>Leukemia , Myeloid , Chronic</keyword>
</DOC>